Loading...
•
Dec 31, 2024
•/
Nyxoah SA Q4 2024 Earnings Report
Nyxoah reported revenue growth but higher operating losses in Q4 2024.
Key Takeaways
Nyxoah's Q4 2024 revenue reached €1.3 million, with a gross margin of 73%. However, increased research and development expenses contributed to a higher operating loss of €18.3 million. The company is preparing for its U.S. commercial launch in March 2025, following anticipated FDA approval.
Total revenue was €1.3 million, impacted by deferred revenue recognition.
Gross margin improved to 73%, up from 60% in Q4 2023.
Operating loss widened to €18.3 million due to increased R&D spending.
Cash and financial assets increased to €85.6 million from €57.7 million YoY.
Revenue by Segment
Forward Guidance
Nyxoah expects significant growth in 2025, driven by the anticipated U.S. commercial launch of Genio and further expansion in European markets.
Positive Outlook
- FDA approval for Genio expected by the end of Q1 2025.
- Commercial launch in the U.S. scheduled for March 2025.
- Strong cash position of €85.6 million to support expansion.
- Growing demand for Genio in European markets, particularly Germany.
- Continued progress in clinical trials to expand treatment applications.
Challenges Ahead
- High R&D expenses continue to impact profitability.
- Regulatory risks related to FDA approval timeline.
- Uncertain reimbursement landscape in the U.S.
- Significant competition in the OSA treatment market.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...